Dr. Reddy’s Share Price Analyzed
Dr. Reddy’s Laboratories stock increased by 2.08% today, reaching ₹1,250.25. The company’s shares were trading at ₹1,249.65, while the BSE Sensex remained relatively stable. This rise was primarily driven by a positive development regarding a new drug approval.
Key Points
- Dr. Reddy’s stock rose due to EC approval of AVT03.
- AVT03 is a biosimilar of Prolia and Xgeva.
- Prolia treats osteoporosis, Xgeva combats cancer bone complications.
- Alvotech developed AVT03, Dr. Reddy’s handles marketing globally.
- The drug will be sold as Acvybra and Xbonzy.
- Dr. Reddy’s is a leading Indian pharmaceutical company.
The European Commission (EC) has approved AVT03, a biosimilar version of Prolia and Xgeva. These drugs are made by Amgen Inc. Prolia is used to treat osteoporosis, particularly in older men and women who are at risk of fractures. Xgeva is used to prevent bone problems in people with certain cancers and to treat giant cell tumors of the bone.
The approval is significant because it covers all countries within the European Union and the European Economic Area, including Iceland, Liechtenstein, and Norway. It was based on strong research and data from a clinical trial. Dr. Reddy’s Labs and Alvotech have a partnership where Alvotech does the manufacturing and development, while Dr. Reddy’s handles the marketing and selling of the product.
The new drug will be named Acvybra (a pre-filled syringe) and Xbonzy (a vial). Dr. Reddy’s has exclusive rights to sell Acvybra in the United States, and semi-exclusive rights in Europe and the United Kingdom. The company is a major player in the Indian pharmaceutical industry, producing a wide range of medications, including generics, biosimilars, and active pharmaceutical ingredients.
This approval signals a key growth opportunity for Dr. Reddy’s in the global biosimilars market.
